-
Merck’s General Counsel Comments On Humeston Vioxx Verdict in NJ
Kenneth Frazier: Merck’s Vioxx Strategy Is To Defend Each Case, Not Settle On November 3, 2005, Merck’s General Counsel Kenneth Frazier commented on the New Jersey Vioxx defense verdict in the Humeston v. Merck…
-
New Study Suggests Tysabri Not Likely Come Back On Market
FDA Will Determine Whether Risks Outweigh Any Potential Benefit Serious side effects associated with Tysabri may outweigh any potential benefit, according to a study published in early November 2005, such that the once-promising drug…
-
Merck Prevails In Its First New Jersey Vioxx Trial
Humeston Case Ends with Defense Verdict for Merck Merck & Co. got what it wanted in its first New Jersey Vioxx trial: a defense verdict. On November 3, 2005, a New Jersey state court…
-
FDA Announces New Digital Drug Package Inserts / Labels Project
Drug Companies To Submit Digital Versions For All Drugs In Coming Year On November 2, 2005 the FDA announced a new project which will involve drug companies submitting digital versions of drug package inserts,…
-
Wyeth Wins Latest Three Fen-Phen Diet-Drug Cases
Several Hundred Fen-Phen Cases Still Pending and Headed to Trial On October 31, 2005 the drug company Wyeth announced that it had won the latest three fen-phen diet-drug cases: Lee Ann Brunson v. Wyeth;…
-
Biogen and FDA Warn of Severe Skin Reactions To Lymphoma Drug Zevalin
Toxic Epidermal Necrolysis (TEN), Stevens-Johnson Syndrome (SJS), and Erythema Multiforme (EM) In late October 2005 Biogen Idec Inc. and the FDA warned doctors about severe and sometimes fatal skin reactions that have been reported…
